Helsinn and Xediton sign exclusive license and distribution agreement for TRUSELTIQ™ (infigratinib) in Canada

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Related Keywords

China ,Lugano ,Ticino ,Switzerland ,United States ,Canada ,Toronto ,Ontario ,Canadians ,Canadian ,Swiss ,George Gafrey ,Paola Bonvicini ,Riccardo Braglia ,Helsinn Group Vice ,Oncology Center ,International Healthcare ,Xediton Pharmaceuticals ,Drug Administration ,Xediton Pharmaceuticals Inc ,Helsinn Group ,Health Canada Notice Of Compliance ,Group Head Of Communication ,Swiss Biopharmaceutical Group ,Helsinn Group Media Contact ,Health Canada ,Pharmaceuticals Inc ,Helsinn Healthcare ,Project Orbis ,Helsinn Group Vice Chairman ,Health Canada Approved ,Greater Toronto Area ,Group Media Contact ,Health ,Business ,Cancer ,Europe ,Globe Newswire ,